Home
This site is intended for healthcare professionals
Share

Description

This activity is supported by an independent education grant from BMS. This online education program has been designed for healthcare professionals globally, excluding the UK.

Join expert Fernando Martinez, MD, for a practical guide on integrating proactive advance care planning (ACP) into longitudinal ILD management. This session explores how objective clinical triggers, such as functional decline and ILD-GAP stage, signal the need to initiate parallel supportive care discussions alongside disease-modifying treatment.

This is Module Four of Four. Modules One, Two, and Three can be found here.

Session Highlights

  • Initiate advance care planning discussions early, using objective clinical parameters like ILD-GAP staging and functional decline rather than waiting for acute crisis events.
  • Execute empathetic, patient-centered communication strategies that clarify care preferences, treatment goals, and escalation boundaries without jargon.
  • Integrate supportive and palliative care pathways in parallel with ongoing antifibrotic therapies to maintain patient quality of life.
  • Document advance care planning decisions directly within shared dashboards to maintain clear multidisciplinary visibility and continuity of care.

Target Audience

This activity is intended for pulmonologists, rheumatologists, thoracic radiologists, pathologists, pulmonology nurse practitioners, and physician assistants/associates who are central to the diagnosis and management of IPF and PPF. It is also designed for general practitioners, respiratory therapists, pharmacists, and other multidisciplinary healthcare professionals involved in the care of patients with pulmonary fibrosis.

Faculty

Dr Fernando Martinez is a Professor in the Division of Pulmonary Medicine and Interim Chair of the Department of Medicine at the University of Massachusetts Chan Medical School in Worcester, Massachusetts. Holding an MD and MS, he is a leading clinician and researcher with a long-standing commitment to academic medicine, patient care, and multidisciplinary strategies in respiratory medicine.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Fernando Martinez, faculty for this educational activity, has the following relevant financial relationships: Advisor for Lung Therapeutics; Consultant, Advisor, and Speaker for Boehringer Ingelheim and Chiesi; DSMB for Pliant; Researcher for AstraZeneca, Bristol Myers Squibb, Chiesi, DevPro, and Vicore.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-364-H01-P

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 30, 2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 1 November 2026 through to 30 September 2027.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.

This continuing education activity is active starting 1 November, 2026 and will expire on 30 September, 2027.

Estimated time to complete this activity: 10 Minutes

Learning objectives

By the end of this activity participants will be able to:

  • Incorporate risk stratification, high‑resolution imaging, and multidisciplinary assessment to differentiate and diagnose IPF and PPF from other ILDs early and accurately.
  • Implement multidisciplinary diagnostic and management strategies to improve timely recognition, referral, and coordinated care for patients with PF.
  • Apply knowledge of mechanisms of action and clinical evidence to treatment decisions, including patient selection and therapy timing.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

So here we are 18 months later, um, we're trying to impress upon you the value of having some type of a dashboard that would give you sort of hints during the management of the patient. This is now a new kind of flag, and it wasn't that one that's not necessarily related to any specific medication, because here you are sitting with Margaret, you've heard her little uh components there. Uh, and over the last 18 months, you know that she's had an elevated gap score, so she's at advanced risk for progression. And sure enough, the lung function parameters demonstrate that her forced vital capacity has been steadily going downhill. Her DLCO is pretty poopy, and most of. Importantly, she's noticing it. She is now not able to do the same as she was doing before. She's can't go up a flight of stairs, uh, she can't go up a hill, uh, and so part of what we want you to understand within the concept of this sort of holistic multidisciplinary approach is to have a sense that this person is at risk and has had functional decline, but there's been no documentation of uh advanced care approaches. And so here we are 18 months of monitoring her going downhill, and no one's addressed this conversation. So the question here is the gap, and by this, I don't mean ILD gap, but I mean the gap in her care isn't really her numbers, it's that we haven't done a good job in providing this care. And so this is part of what we want to try to impress upon you the importance of looking at something like, so this is your hypothetical, uh, dashboard, and what you're looking at is, OK, there's a little. Warning on Margaret, uh, who's got, uh, rheumatoid arthritis and associated ILD. She's had an elevated gap stage, so sort of physiologically and clinically, we know she's at risk. In fact, we've documented that there's progression in her pulmonary functions, and she's symptomatically noticing it. And when we look at our, our concepts of advanced uh care planning, That there's just no clear documentation that we've addressed, uh, what she wants, uh, how she wants to be managed, goals of care, place of care, what she wants to do therapeutically and non-ph pharmaco therapeutically for sort of escalation preferences, and there's no evidence that there's been any advanced care planning in her record. Uh, and I think that, that's where we want. To adjust ourselves, our practice pattern, to avoid this gap in care, which is to address the progressive nature of this disorder. So here we come back to, um, to Margaret. Uh, we, we've got a clinician who's talking with her, uh, and, and I want you to sort of to, to look at the way this interaction takes place, uh, and think about it if this were you, uh, what was good. What was that good? What could have been done better? What tools could I have used to better support this, uh, discussion and, and see what, how you guys would, would, would manage this, uh, in, uh, in Margaret's case. Margaret, good to see you. So your numbers, the breathing test has dropped again, and your gap stage is now a 2, which does change the trajectory conversation. I noticed there's no advanced care planning documentation on file, so we should really get that sorted today. It's just a form, nothing to worry about, a form. Is this because it's getting worse? Well, the decline does meet, um, progression thresholds, but let's not get ahead of ourselves. Basically, we document your preferences, resuscitation, escalation, that kind of thing. So it's all on file. Some people involve family, that's an option. Does that sound OK? I suppose. I'd have to think. Great. Reception can print the paperwork and we'll pick it up at your next visit. You're doing really well, all things considered. Right. Thank you, doctor. I'll tell you my impression was that this was, you know, it was a well meant discussion, but it was kind of a little bit rushed and a lot of jargon that was being used, um, and as we come back to trying to get a sense of proactive care, using a dashboard like we've sort of presented for you to, to highlight for us, understand we've got an at-risk person, because you know, there, there's already a, a methodology that's been introduced to identify high-risk individuals. In this case, you, you know that she's at risk. Uh, as you progress in parallel, you're treating, you're monitoring, in her case, you saw her lung function going in that direction, and, and so you're supporting her with management of whatever therapeutic approach you've taken. At the same time, we wanna have you be able to understand in a person like Margaret. It's important to be able to be proactive in asking, what do you wanna do? What matters to you? What, what are your goals, uh, Margaret? Um, how do you wanna achieve those? Do you wanna do it pharmacologically, non-pharmacologically? Uh, do you wanna do it here or you wanna do it in a different location? And all of that has to be documented so that all of your colleagues that are involved in her care get a good sense of, of this approach to proactive management from the earliest stage of disease. To what we do as the stage progresses in appropriately establishing goals, plans, and maximizing satisfaction for all involved, particularly Margaret. Uh, and so this advanced care planning is not really the end of treatment. It's sort of like a safety rail that runs in parallel to, to maximize the outcomes that occur. So if, if I were gonna take away my impressions from, from this, uh, this presentation, the goal of what we're trying to achieve is that advanced care planning is longitudinal. It is, it's not dealing with whenever there's a crisis, uh, it is something that's based on the, the baseline assessment and then a very careful discussion with the patient of what the patient wants. Where she wants to do the care and, and what she wants as her ultimate goals, that, that same dashboard that guards adherence should aid you in management the conversation. This documentation of those discussions in your advanced care plan is gonna be useful for you, for Margaret, and for any other clinician that's involved in her care. And, and the idea of being supportive and being able to provide disease modifying therapy which we now have sort of runs in parallel. That, that's an, an advantage for you. It's an advantage most importantly for the patient. And so neither of those cancels the other. They're this joint uh care. I warned you this was coming again. So here's your poll. Again, the same question we asked earlier, how confident are you that you would recognize and act on early ILD management in a patient like Margaret? Same options from not at all confident all the way to completely confident. Uh, and so let's see how that's changed over the course of the last hour. All right. Here we come back to Margaret. Uh, so you, you know, gone through the diagnosis. Um, we, we've sort of asked Margaret, OK, listen, what do you think, uh, you would have wanted, uh, to have happened earlier? You, from the patient's point of view, it was important insight. What's your stance, Margaret? Let's see what she says. I don't think anyone did anything wrong, exactly, but my care team knew my lungs could be affected. I didn't. I wish that had been checked before I could feel anything, and I wish someone had clearly overseen the results and the conversation about what matters to me. I'd have been ready for that much earlier than anyone asked. All right. So, most importantly, when you participate in a program like this, to try to remember at least one thing that, that you're going to do differently. Uh, and so these are, these are potentially options, uh, for you to consider. It's most importantly for you in your practice setting. Uh, know what a risk profile looks like, um, so that you, you're establishing some thoughts regarding how you want to interact with Margaret before any symptoms occur, certainly before there's any crisis that's occurred. Uh, put that as a flag to yourself and act on that, uh, when you have an opportunity, um, give every flag an owner, so whenever you're documenting these components, in particularly if you have structured reports, which always simplify things, make sure that there's good documentation that you address these components of the advanced care planning. So that the multidisciplinary discussion, which is the gold standard for all of us in diagnosis and management, becomes part of the routine for all clinicians that are involved with managing Margaret during the course of her, of her journey, uh, and then, you know, treat tolerability as a treatment. You know, all of these drugs have challenging components, some less, some more. Be proactive in managing some of the particularly GI side effects with the patient. There is a, a, a broad, it's amazing the, the level of advance we've made in therapy and it's continuing to proceed. So, so Margaret's gonna have a lot of options, and so you're gonna have to really be able to document all of that, make sure that you've had those discussions with Margaret, they're recorded in your, in your action plan, and you close the loop with the patient. Because what, what's most important is what matters to her during the course of this longitudinal journey with you and aiding her with her care.